S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
NASDAQ:ERAS

Erasca - ERAS Stock Forecast, Price & News

$4.04
+0.13 (+3.32%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.90
▼
$4.11
50-Day Range
$3.75
▼
$7.61
52-Week Range
$3.60
▼
$12.80
Volume
1.00 million shs
Average Volume
922,131 shs
Market Capitalization
$494.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Erasca MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
11.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Erasca in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$2.57 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.20) to ($1.39) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

693rd out of 1,055 stocks

Pharmaceutical Preparations Industry

351st out of 519 stocks

See Top Rated MarketRank™ Stocks Here

ERAS stock logo

About Erasca (NASDAQ:ERAS) Stock

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Stock News Headlines

January 21, 2023 | americanbankingnews.com
Head to Head Survey: Erasca (NASDAQ:ERAS) and Longboard Pharmaceuticals (NASDAQ:LBPH)
January 16, 2023 | finance.yahoo.com
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 11, 2023 | benzinga.com
Erasca Chairman & CEO Makes $231K Stock Purchase
January 4, 2023 | finance.yahoo.com
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 | finance.yahoo.com
Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors
December 17, 2022 | finance.yahoo.com
Co-Founder Jonathan Lim Just Bought A Handful Of Shares In Erasca, Inc. (NASDAQ:ERAS)
December 16, 2022 | finance.yahoo.com
Erasca, Inc.'s (NASDAQ:ERAS) recent 16% pullback adds to one-year year losses, institutional owners may take drastic measures
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
December 13, 2022 | msn.com
Erasca receives FDA clearance to begin trial of non-small cell lung cancer treatment
December 13, 2022 | finance.yahoo.com
Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
December 9, 2022 | marketwatch.com
Erasca Shares Drop 30% After Pricing of $100M Underwritten Offering, Novartis Agreement
December 9, 2022 | markets.businessinsider.com
Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering
December 9, 2022 | seekingalpha.com
Erasca to pay $20M upfront to Novartis in license deal for potential cancer drug
November 30, 2022 | markets.businessinsider.com
Erasca To Work With Pierre Fabre To Explore ERAS-007 In Combination With Encorafenib, Cetuximab
November 30, 2022 | finance.yahoo.com
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
November 22, 2022 | finance.yahoo.com
Erasca to Present at Upcoming Investor Conferences
November 14, 2022 | finance.yahoo.com
Wall Street Analysts Predict a 126% Upside in Erasca, Inc. (ERAS): Here's What You Should Know
November 13, 2022 | finanznachrichten.de
Erasca, Inc.: Erasca Reports Third Quarter 2022 Financial Results and Business Updates
November 9, 2022 | finance.yahoo.com
Erasca Reports Third Quarter 2022 Financial Results and Business Updates
October 20, 2022 | finance.yahoo.com
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
October 12, 2022 | finance.yahoo.com
Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium
September 26, 2022 | finance.yahoo.com
Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022
September 8, 2022 | msn.com
Peering Into Erasca's Recent Short Interest
September 7, 2022 | finance.yahoo.com
Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials
August 24, 2022 | finance.yahoo.com
Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors
August 23, 2022 | finance.yahoo.com
Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers
See More Headlines
Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Company Calendar

Last Earnings
11/09/2022
Today
1/28/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ERAS
CUSIP
N/A
CIK
1761918
Web
www.erasca.com
Phone
858-465-6511
Fax
N/A
Employees
123
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-122,760,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-33.63%
Return on Assets
-29.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.21
Quick Ratio
13.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.77 per share
Price / Book
1.07

Miscellaneous

Outstanding Shares
122,360,000
Free Float
76,476,000
Market Cap
$494.33 million
Optionable
Not Optionable
Beta
1.27

Key Executives

  • Dr. Jonathan E. Lim M.D. (Age 51)
    Co-Founder, Chairman & CEO
    Comp: $850.23k
  • Mr. Ebun S. Garner J.D. (Age 51)
    Esq., Gen. Counsel & Corp. Sec.
    Comp: $510.98k
  • Dr. Wei Lin M.D. (Age 53)
    Chief Medical Officer
    Comp: $1M
  • Dr. Michael D. Varney Ph.D. (Age 65)
    Chairman of R&D, Scientific Advisory Board Member and Director
    Comp: $78.38k
  • Dr. David M. Chacko M.D. (Age 39)
    Chief Financial Officer
  • Dr. Nik Chetwyn Ph.D.
    Sr. VP of Operations
  • Dr. Lisa Tesvich-Bonora Ph.D.
    Chief People Officer
  • Mr. Brian L. Baker CPA (Age 56)
    M.S., MS, CPA, Sr. VP of Fin.
  • Ms. Chandra D. Lovejoy (Age 52)
    Sr. VP of Regulatory Affairs
  • Dr. Robert Shoemaker Ph.D. (Age 42)
    Sr. VP of Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ERAS Stock - Frequently Asked Questions

How have ERAS shares performed in 2023?

Erasca's stock was trading at $4.31 on January 1st, 2023. Since then, ERAS shares have decreased by 6.3% and is now trading at $4.04.
View the best growth stocks for 2023 here.

Are investors shorting Erasca?

Erasca saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 8,060,000 shares, a decrease of 22.9% from the December 31st total of 10,460,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is presently 7.5 days. Approximately 11.6% of the shares of the company are sold short.
View Erasca's Short Interest.

When is Erasca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our ERAS earnings forecast.

How were Erasca's earnings last quarter?

Erasca, Inc. (NASDAQ:ERAS) released its earnings results on Wednesday, November, 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.02.

When did Erasca IPO?

(ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.

What is Erasca's stock symbol?

Erasca trades on the NASDAQ under the ticker symbol "ERAS."

How do I buy shares of Erasca?

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Erasca's stock price today?

One share of ERAS stock can currently be purchased for approximately $4.04.

How much money does Erasca make?

Erasca (NASDAQ:ERAS) has a market capitalization of $494.34 million. The company earns $-122,760,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does Erasca have?

The company employs 123 workers across the globe.

How can I contact Erasca?

The official website for the company is www.erasca.com. The company can be reached via phone at 858-465-6511 or via email at ir@erasca.com.

This page (NASDAQ:ERAS) was last updated on 1/28/2023 by MarketBeat.com Staff